M AINTENANCE of bone volume in premenopausal adulthood depends on a balance between osteoclastmediated bone resorption and osteoblast-mediated bone formation. Once a volume of bone is removed by osteoclast activity, it is replaced by an approximately equal amount of newly formed bone. This sequence of events requires communication between osteoclasts and osteoblasts and suggests the generation of paracrine and autocrine regulatory factors by these cells. The precision evident in the balance between bone resorption and bone formation supports the hypothesis that these processes must be closely regulated by multiple factors. It is probable that some of these factors are generated within the local environment and function as autocrine and/or paracrine factors. It is also likely that some of these factors are present in the bone matrix and are released as the result of osteoclast resorption activity (1, 2). Further, it is possible that osteoclasts may synthesize and secrete substances that can act as both autocrine and paracrine factors to influence the bone remodeling sequence. Given the multiple influences of transforming growth factor-/3 (TGFfl) within the bone environment, it is possible that members of this family are candidates for such a role (3-7).
The TGF@ constitute a family of multifunctional proteins with a wide range of biological activities (reviewed in Ref.
3). Members of this family have been implicated in bone me-tabolism at several levels. There are conflicting reports in the literature concerning the nature of these effects that may at least in part be attributable to differences in the systems examined and culture conditions (reviewed in Ref. 4). In contrast to the wealth of studies on the effects of TGFP on osteoblast activity and osteoclast differentiation, there are fewer reports of the effects of TGFfi on osteoclast activity. TGFfl has been shown to decrease differentiation of osteoclast-like cells in vitro as well as either stimulate or repress in z&J bone resorption in organ culture systems (Refs. 5-12 and references therein).
Estrogen plays an important role in maintaining bone mass in adult women by suppressing bone remodeling and maintaining a balance between osteoblastic and osteoclastic activity (13, 14) . The presence of estrogen receptors in boneforming osteoblasts and the lack of substantial effects of estrogen on osteoblast proliferation and differentiation suggested that estrogen might act through an osteoblast-derived paracrine factor to influence resorption (15-17). We have also identified functional estrogen receptors in avian osteoclasts and human osteoclast-like cells obtained from giant cell tumors of the bone (18, 19 
Results
Initially, we examined a broad range of estrogen concentrations to assess changes in total TGF/3 production by osteoclasts (Fig. 1) . After 24 h of culture of osteoclasts with 10-i' or lo-ii M estrogen, there was no change in TGFP protein accumulation. However, when cultures were treated with higher concentrations of estrogen, there was a dose- dependent increase in TGFfi accumulation in the culture medium. Northern blot analysis of the TGF&, -pa, and -& mRNA levels after 30 min and 1, 2, and 18 h of treatment demonstrated that there appeared to be an increase in the mRNA levels for all isoforms of TGFP relative to those in the vehicle control at early time points after lo-M estrogen treatment (Fig. 2) . Increases in TGFfl protein were detectable after 4 h of culture and continued throughout the 24-h period of culture (Fig. 3) . This response appeared to be specific for estrogen, as parallel cultures of the inactive stereoisomer 17a+estrogen had no effect on TGF/3 accumulation (Fig. 4) . Moreover, cotreatment of osteoclast cultures with 10U9 M estrogen and lo-' M of the estrogen antagonist ICI 182780 partially inhibited the increase in osteoclast TGFP production (Fig. 4) . Identification of the TGFP isoforms in the conditioned medium was accomplished by immunoprecipitation and removal of all detectable TGFP in the conditioned medium using antibody preparations that specifically recognize TGF&, -& or -/3a and a preparation that recognizes all of the isoforms of TGF/3 (Table 1 and treated osteoclasts secrete primarily TGFf12, whereas estrogen-treated osteoclasts secrete primarily TGF& in their media. Treatment of isolated osteoclast cultures with estrogen decreases the secretion of lysosomal enzymes within 18-24 h of treatment (27). As osteoclast-mediated activation of TGF/3 is likely to involve secreted proteases (21), we examined the influence of estrogen on the accumulation of active TGF/3 in the culture medium. These studies demonstrated a steroid dose-dependent decrease in active TGF/3 after 24 h of culture with estrogen (Fig. 6) . The higher level of TGFP production observed in this series of experiments is probably due to the higher cell number per sample point used. Isolated osteoclasts were cultured with either ethanol or 10-s M estrogen for 24 h. The conditioned medium was harvested, acid activated, and immunoprecipitated with antibodies to the indicated isoform(s) to remove TGF6 before quantitation of the remaining TGF6 protein levels in the conditioned media.
a The amount of TGF6 activity removed by each of the antibodies was determined by subtracting the residual detected activity of each sample from the activity level of the aliquot treated with no primary antibody.
'P < 0.01 comparing estrogen treated with vehicle control. 'P < 0.01, comparing antibody treated to no primary antibody treated.
These data are from a single experiment analyzed in triplicate. The results of three such experiments are presented in Fig. 5 . Isolated osteoclasts were cultured with either ethanol or 10-s M estrogen for 24 h. The conditioned medium was harvested, acid activated, and immunoprecipitated with antibodies to the indicated isoform(s) to remove TGF/3 before quantitation of the remaining TGF6 protein levels in the conditioned medium. The amount of TGF6 activity removed by each of the antibodies was determined by subtracting the residual detected activity from each sample from the preprecipitation activity level. *, P < 0.01 comparing specific isoforms to all precipitations; **, P < 0.01 comparing estrogen treated with vehicle control.
Discussion
These studies demonstrate that estrogen modulates the synthesis, secretion, and activation of latent TGFB by avian osteoclasts. We have previously shown that in our osteoclast preparations, the contaminating mononuclear cells produce approximately 20-fold less TGFB than the osteoclasts (21). Moreover, the mononuclear cells do not express mRNA for the estrogen receptor, strongly supporting the possibility that the effects of estrogen demonstrated here are the result of direct actions of estrogen on osteoclasts (191. harvested and split into two aliquots each, half was activated before assay (to determine the total TGF6 protein concentration), and the other half was assayed without acid activation (to determine the concentration of active TGF6 protein present before acid activation). Both aliquots were then assayed to determine the amount of active TGF6 detectable. *, P < 0.001 compared with vehicle control.
We have examined TGF& -&,, and +a protein while probing for TGF&, -&, and -& steady state mRNA levels. The reason for examining TGF& protein and TGF& mRNA is that molecular phylogeny strongly supports that the cDNA that has been identified as avian TGF/34 is actually the avian homolog of TGF& (281. Further, the previously reported isolation of avian TGF& cDNA was in error, and the identified cDNA has been proven to be a contaminating cDNA for porcine TGF& (Dr. Anita Roberts, personal communication). Densitometric analysis of the Northern blots support that there are elevations in the mRNA for all isoforms of TGF/3 compared to that in vehicle controls at early time points. Careful examination of the blots reveals that this apparent increase is due to a markedly lower level of TGF/3 mRNA detection in each of the respective vehicle samples. Subsequent probing of the blots with osteopontin was carried out to standardize for loading and transfer of RNA, because we observed that estrogen treatment of osteoclasts does not influence osteopontin mRNA or protein levels four unpublished data). Osteopontin levels in the vehicle-treated samples in question were somewhat lower, but not sufficiently low to account for the lower TGF/3 mRNA values. Thus, the reason for the demonstrated lower levels of TGFP mRNA in the vehicle-treated samples remains unclear, and resolution of this question will require further investigation. However, we conclude from our data that it is unlikely that the measured increase in TGFfi protein demonstrated here is due solely to transcriptional regulation. We have shown that freshly isolated osteoclasts express the mRNA for several TGFP isoforms, but synthesize and secrete primarily TGF& (211. These data suggest that there is regulation at the posttranscriptional level of TGF/3 synthesis and secretion by osteoclasts. The data presented here suggest that estrogen may alter the synthesis and secretion of osteoclast TGFP protein by posttranscriptional mechanisms. Given the effects of estrogen on osteoclast lysosomal enzyme production and secretion, the alteration in the secretion of TGF/3 demonstrated here may also involve altered posttranslational processing (27). The possibility that there are multiple levels of regulation of TGF/3 synthesis and secretion is supported by reports of estrogen modulation of TGF/3 synthesis in breast cancer cell lines without changes in steady state mRNA levels G9.
We have previously demonstrated that osteoclasts secrete a mixture of proteases that activate latent TGFP (211. Experiments reported in the literature have demonstrated multiple mechanisms by which TGFP may be activated in r&o. Cocultures using a variety of cell types result in activation of latent TGFP by an activation mechanism that requires the interaction between two different cell types that is dependent on cell-cell contact (30,311. Moreover, latent TGFfl has been reported to be activated in a number of cell types after hormonal stimulation, including retinoic acid treatment in keratinocytes, antiestrogen treatment in fetal fibroblasts, and glucocorticoid treatment in mesenchymal cells or osteoblasts (32-35). We have demonstrated previously that estrogen treatment of isolated osteoclasts decreases the synthesis and secretion of lysosomal enzymes (271. Therefore, it is likely that the decrease in osteoclast-mediated activation of TGFP in response to estrogen reported in this paper is due to decreased secretion of lysosomal proteases. Elucidating the physiological role of this decrease in osteoclast-mediated activation by estrogen will require further investigation. However, considering the large amount of in vitro and in vim data on the effects of TGF/3 on bone metabolism, it is likely that these processes and/or pathways will be important and probably involve modulation of the secretion of proteases that activate the latent TGFP.
Studies in vim have shown that TGFP increases bone formation, whereas in vifro studies on the actions of TGF/3 on osteoblasts are conflicting (36-40). Using normal human osteoblast-like cells, we have demonstrated that TGF/3 is a potent mitogen for osteoblasts (41). Studies on the effects of TGF/3 on both bone resorption and osteoclast differentiation have also been conflicting (5-121. This may be due to differences in the model system examined, concentration of growth factor used, and/or TGFP isoform studied. Studies of the effects of TGFP on bone resorption have been carried out thus far only in organ cultures in which the myriad of cell types makes it impossible to identify the target cells for the action of the growth factor under study. Moreover, the complex interactions and experimental artifacts (such as elevated PG levels due to surgical removal of the organ) make it difficult to define the effects of TGFP alone on osteoclast activity.
The biological differences among the various TGF/3 isoforms are unresolved in many tissue systems, but their differential expression in embryonic development has been reported (42-46). Thus far, no difference in the effects of the different isoforms on osteoblast activities have been reported, although TGF& is significantly more potent on a molar basis than is TGF& or TGF& on osteoblasts, and there is an emerging body of evidence supporting differential effects of the different isoforms in other tissues (47) (48) (49) (50) . In any case, the significance in the change in types of isoforms with Ez treatment is unclear and will require further investigation. TGF&, -&, and -pa are all expressed in bone tissues during embryonic development, but there are both spatial and temporal differences in their expression (42-46). These data support a differential role for the different isoforms in bone development. It is also possible that different isoforms may have different roles in bone metabolism and be involved in the coupling of new bone formation and bone resorption. It is, therefore, possible that the increased production of more potent isoforms of TGFP may affect bone metabolism significantly. These possibilities will also require further investigation. As bone is the largest storage compartment for latent TGF/3 within the body, elevation in the production of TGFP by osteoclasts, which are present in small numbers in mature bone, is by itself not likely to significantly alter the amount of TGFP present within the bone environment (51) . The significance of the observations reported here probably includes the alteration in the isoform being secreted as well as the additional decrease in osteoclast-mediated activation of TGF/3.
The work of many laboratories now supports a major role for TGF/3 in estrogen regulation of bone metabolism. It is a likely hypothesis that a significant amount of the reported effects of estrogen on bone cells in culture and bone metabolism in vim could be mediated by estrogen modulation of TGFP production and/or activation. It is possible that TGF/3 may play a role in modulating the direct action of estrogen on the inhibition of osteoclast bone resorption activity. Moreover, as latent TGF/3 must be activated to affect cellular activities, the decrease in TGF/3 activation after estrogen treatment, which suggests that there may be a decrease in osteoclast-mediated activation of TGFP in viva, could have profound effects on bone metabolism. This decrease in active TGFj3 may be offset by the change in isoform to a more potent p3 isoform to compensate for the lower concentration of active TGF/3, or the isoform switch may have other, as yet unrecognized, consequences. These hypotheses currently are under investigation. Taken together, our data support the hypothesis that among potential osteoclast-inhibiting cytokines produced within the bone environment, a major candidate for mediating estrogen action on bone metabolism is TGF/3. 
